Eli Lilly and UnitedHealth Group announced early last month that they are teaming up to conduct a “pragmatic” study of Lilly’s bamlanivimab, a monoclonal antibody developed as a treatment for COVID-19.
Eli Lilly and UnitedHealth Group announced early last month that they are teaming up to conduct a “pragmatic” study of Lilly’s bamlanivimab, a monoclonal antibody developed as a treatment for COVID-19. The FDA’s emergency use authorization of bamlanivimab limits it use to patients who have not been hospitalized.
UnitedHealthcare Medicare Advantage members will be invited to participate. Study volunteers will use a symptom-checker app developed by Optum, which is part of UnitedHealth. If they experience symptoms, they will take a self-
administered test for SARS-Cov-2, the virus that causes COVID-19. An Optum Infusion Pharmacy nurse will oversee at-home infusions of bamlanivimab. Many non-COVID-19 patients getting treated at infusion centers are immunocompromised, so home infusion of this treatment might very well have some safety advantages. The primary outcome measure is hospitalizations in the 28-day period after the drug is infused.
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Healthcare journalist, HIV advocate and educator Juan Michael Porter II discussed moderating the "Future of Science" session at the International AIDS Society's AIDS 2024 meeting in Munich, Germany, as well as addressing "founder's syndrome" in AIDS organizations and the inclusivity of the event.
Read More
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen